Hugh M. Cole is Chief Business Officer and Head of Corporate Development at Jounce Therapeutics. His responsibilities at Jounce include Corporate Strategy, Business Development, Alliance Management, Program and Portfolio Strategy, and New Product Planning. Mr. Cole has more than 25 years of experience in the pharmaceutical/biotech industries. Prior to Jounce, Mr. Cole most recently served as chief business officer for ARIAD Pharmaceuticals, where he led several transactions and helped develop and implement ARIAD’s new corporate strategy before its acquisition by Takeda Pharmaceuticals. Prior to ARIAD, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, where he oversaw the company’s portfolio management and rare disease strategic planning processes. At Shire, Mr. Cole was also globally responsible for the development strategy and commercialization of the rare disease drug Firazyr®, and led several important transactions for the company. Mr. Cole began his biotech career at Millennium Pharmaceuticals, and prior to that, worked as a management consultant for The Wilkerson Group, a leading consultancy focused on life science companies.

Mr. Cole earned his MBA in health care management and finance at the Wharton School and his A.B. in chemistry from Harvard University.